JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Koster, A. Articles by Levy, J. H. Search for Related Content PubMed PubMed Citation Articles by Koster, A. Articles by Levy, J. H. Related Collections Cardiovascular Blood Heart Monitoring (Cardiac)

---

CARDIOVASCULAR ANESTHESIA

The Plasma Supplemented Modified Activated Clotting Time for Monitoring of Heparinization During Cardiopulmonary Bypass: A Pilot Investigation

Andreas Koster, MD^*, George Despotis, MD, Marcus Gruendel, MD^*, Thomas Fischer, MD^*, Michael Praus, MD, Herman Kuppe, MD^*, and Jerrold H. Levy, MD

*Department of Anesthesia, Deutsches Herzzentrum, and Institute of Pathobiochemistry and Clinical Chemistry, Charité, Campus Virchow, Berlin, Germany; Departments of Anesthesiology, Pathology, and Immunology, Washington University School of Medicine, St Louis, Missouri; and Department of Cardiothoracic Anesthesiology, Emory University School of Medicine, Atlanta, Georgia

Address correspondence and reprint requests to Andreas Koster, MD, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Address e-mail to Koster{at}dhzb.de

The standard celite or kaolin activated clotting time (ACT) correlates poorly with heparin levels during cardiopulmonary bypass (CPB). We compared a modified kaolin ACT, in which plasma was supplemented, to a standard undiluted kaolin ACT for monitoring heparin levels during CPB. Fifteen patients undergoing normothermic CPB were enrolled in this prospective study. Heparin management was performed according to the Hepcon HMS results (Medtronic, Minneapolis, MN). The ACTs were performed with the ACT II device (Medtronic). Hepcon HMS calculations, standard kaolin ACTs, and plasma supplemented modified ACTs (mACTs), prepared by diluting blood samples 1:1 with human plasma (Behring, Marburg, Germany), were measured every 30 min during CPB. The data obtained were correlated to the plasma chromogenic anti-Xa activity as a reference assay for heparin levels. A total of 64 samples were evaluated. The chromogenic anti-Xa activity ranged from 0.2 to 5.5 IU/mL. The Hepcon HMS calculations ranged from 2.7–8.2 IU/mL of heparin, the standard ACT ranged from 424 to >999 s, and the mACT ranged from 210 to 801 s. The correlation to the chromogenic anti-Xa method was r = 0.43 for the standard kaolin ACT and r = 0.69 for the plasma mACT. The plasma mACT provided an improved correlation to chromogenically measured levels of anti-Xa activity during CPB. The improved correlation most likely results from a correction of the effects of the impairment of the coagulation system caused by hemodilution and consumption of procoagulants on extracorporeal surfaces.

IMPLICATIONS: During cardiopulmonary bypass, the plasma modified kaolin activated clotting time (ACT) provides a better correlation with heparin levels than the standard kaolin ACT.

This article has been cited by other articles:

				C. W. Baird, D. Zurakowski, B. Robinson, S. Gandhi, L. Burdis-Koch, J. Tamblyn, R. Munoz, K. Fortich, and F. A. Pigula Anticoagulation and Pediatric Extracorporeal Membrane Oxygenation: Impact of Activated Clotting Time and Heparin Dose on Survival Ann. Thorac. Surg., March 1, 2007; 83(3): 912 - 920. [Abstract] [Full Text] [PDF]

				J. J. Chavez, D. E. Foley, C. C. Snider, J. C. Howell, E. Cohen, R. A. Muenchen, and R. C. Carroll A Novel Thrombelastograph(R) Tissue Factor/Kaolin Assay of Activated Clotting Times for Monitoring Heparin Anticoagulation During Cardiopulmonary Bypass Anesth. Analg., November 1, 2004; 99(5): 1290 - 1294. [Abstract] [Full Text] [PDF]

				S Svenmarker, M Appelblad, E Jansson, and S Haggmark Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec(R) ACT and Hemochron(R) Jr apparatus Perfusion, September 1, 2004; 19(5): 289 - 294. [Abstract] [PDF]

				A. Koster, D. Chew, M. Grundel, M. Bauer, H. Kuppe, and B. D. Spiess Bivalirudin Monitored with the Ecarin Clotting Time for Anticoagulation During Cardiopulmonary Bypass Anesth. Analg., February 1, 2003; 96(2): 383 - 386. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999